Jazz Pharmaceuticals plc 4

Director Norbert G. Riedel received an award of 1,605 Jazz Pharmaceuticals plc RSUs/ordinary shares at no cost as part of director compensation.

On August 5, 2026, non-employee director Norbert G. Riedel received an award of 1,605 restricted stock units (RSUs) of Jazz Pharmaceuticals plc under the company’s 2007 Amended and Restated Non-Employee Directors Stock Award Plan, each RSU representing the right to receive one ordinary share upon vesting, with the units scheduled to vest in full on July 23, 2027, subject to continued service and other conditions. The transaction was coded as an acquisition at no cost and increased his direct holdings to 8,629 ordinary shares, while he also has 10,630 shares held indirectly through the NORBERT G. RIEDEL 2023 TRUST, an entity owned and controlled by him and his immediate family. No open-market purchases or sales occurred; this filing reflects routine equity compensation for board service rather than discretionary trading activity.

Filing Facts

CIK

1232524

Ticker

JAZZ

Form

4

Source Type

fda

Accession

0001161662-26-000005

Alert Tier

5